Sartorius Stedim Biotech is a leading provider of tools for biopharmaceutical fermentation and fluid management. Parent Sartorius AG has a 74% stake in the company, with 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (38% of 2022 sales), the Americas (36%), and Asia-Pacific (26%). Sartorius Stedim Biotech employs over 10,000 people and has operations in more than 20 countries.
Quote | Sartorius Stedim Biotech (OTCMKTS:SDMHF)
Last: | $160 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $160 |
High: | $0 |
Low: | $0 |
Volume: | 26,458 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Sartorius Stedim Biotech (OTCMKTS:SDMHF)
2024-07-19 19:15:20 ET Sartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Conference Call July 18, 2024, 13:45 AM ET Company Participants Dr. Joachim Kreuzburg - IR Rene Faber - Head of Bioprocess Solutions Division & Member Dr. Florian Funck - CFO ...
2024-07-19 06:14:11 ET More on Sartorius Stedim Biotech S.A. RGA Investment Advisors - Sartorius: Purity In The Pure Play Of Bioprocessing Sartorius AG: It's A Good Long-Term Play, But 'Wait And See' Approach Is More Conservative Now Read the full article on Seekin...
Message Board Posts | Sartorius Stedim Biotech (OTCMKTS:SDMHF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest Sartorius Stedim Bio (SDMHF) Headlines Bioseparation Systems for Global Biopha | Stock_Tracker | investorshangout | 03/11/2014 11:25:12 AM |
chartguy89: SDMHF 204.3561 Stock Charts $SDMHF 1 Month Chart | chartguy89 | investorshangout | 03/09/2014 9:50:47 PM |
chartguy89: SDMHF Stock Charts Last: +8.0218 Saturday, March 1, 2014 at 1:11:17 PM $SDMHF 1 | chartguy89 | investorshangout | 03/01/2014 6:11:29 PM |
News, Short Squeeze, Breakout and More Instantly...
Sartorius Stedim Biotech Company Name:
SDMHF Stock Symbol:
OTCMKTS Market:
Nine-month results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent Overall market situation characterized by innovations and strong growth drivers; current development as ex...
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...
Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...